2310035C23Rik Inhibitors encompass a range of compounds, each designed to interact with various cellular mechanisms that can indirectly influence the activity of the protein encoded by the gene 2310035C23Rik. This class includes inhibitors such as Wortmannin and LY294002, both of which are recognized for their role in inhibiting phosphoinositide 3-kinases (PI3K). The inhibition of PI3K by these compounds indicates a strategic approach to modulating signaling pathways, potentially affecting the functional dynamics of 2310035C23Rik. Wortmannin, with its specific interaction with PI3K, and LY294002, with its broader impact on various signaling pathways, exemplify the methodology of targeting key enzymes in relevant signaling cascades to achieve modulation of the target protein's activity.
Expanding the scope of this chemical class, other compounds like Rapamycin and Bortezomib play significant roles. Rapamycin, an mTOR inhibitor, is instrumental in regulating pathways critical for cell growth and survival, offering a method to influence the pathways associated with 2310035C23Rik. This highlights the concept of targeting major regulatory pathways to control specific protein functions. Bortezomib, focusing on proteasomal degradation pathways, presents a different approach where the modulation of protein stability and turnover can impact the activity of 2310035C23Rik. The inclusion of kinase inhibitors like Staurosporine and PD98059, which offer broad-spectrum inhibition and specific targeting of the MEK pathway, respectively, further diversifies this class. Staurosporine's ability to inhibit a wide range of kinases and PD98059's focused action on MEK1/2 underscore the versatility in targeting either a broad spectrum of kinases or specific ones to achieve desired modulation of 2310035C23Rik. Additionally, compounds such as 5-Azacytidine and Trichostatin A, which act on epigenetic mechanisms, are part of this class. They influence gene expression patterns, providing avenues to modulate the expression of proteins like 2310035C23Rik. The diversity of these chemicals, in their targets and mechanisms, underscores the complexity of cellular signaling and the multitude of ways in which the activity of a specific protein like 2310035C23Rik can be modulated. This complexity is echoed in the inclusion of Cyclopamine, an inhibitor of the Hedgehog signaling pathway, and SB203580, a specific inhibitor of p38 MAP kinase, reflecting the broad spectrum of cellular processes and pathways that can be leveraged to influence the function of target proteins such as 2310035C23Rik.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, affecting signaling pathways that might be relevant to 2310035C23Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, has shown to influence pathways that intersect with 2310035C23Rik's regulatory mechanisms. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A broad-spectrum protein kinase inhibitor, affecting kinases related to 2310035C23Rik's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, impacting various signaling pathways that has shown to be relevant to 2310035C23Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, modulating the MAPK pathway associated with 2310035C23Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Specifically inhibits p38 MAP kinase, affecting stress response pathways involving 2310035C23Rik. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Acts on DNA methylation, has shown to affect gene expression linked to 2310035C23Rik. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor, impacting chromatin dynamics related to 2310035C23Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, has shown to influence apoptosis and differentiation pathways related to 2310035C23Rik. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Inhibits the Hedgehog signaling pathway, affecting pathways associated with 2310035C23Rik. | ||||||